Sugi Predict

Sugi Predict / Compounds / SCHEMBL5900901

SCHEMBL5900901

SCHEMBL5900901

CCCCCCCCCCCCC(C(=S)Nc1cc(C)c(O)c(C)c1C)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SOAT2 O75908 1/20 0.57
▸ ACAT1 P24752 1/20 0.57
▸ SOAT1 P35610 1/20 0.57
▸ LMNA P02545 5/20 0.34
▸ ALOX12 P18054 3/20 0.34
▸ HTT P42858 3/20 0.34
▸ MAPT P10636 3/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ ASAH1 Q13510 1/20 0.34
▸ ACER2 Q5QJU3 1/20 0.34
▸ ALOX5 P09917 6/20 0.33
▸ NAAA Q02083 2/20 0.33
▸ ALPL P05186 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL668293 1.00 SOAT2 (0.57) SOAT2ACAT1SOAT1LMNAALOX12
SCHEMBL8416085 0.87 SOAT2 (0.44) SOAT2ACAT1SOAT1LMNAALOX12
SCHEMBL8417196 0.84 SOAT2 (0.42) SOAT2ACAT1SOAT1LMNAMAPT
SCHEMBL8417517 0.83 SOAT1 (0.47) SOAT2ACAT1SOAT1LMNAMAPT
SCHEMBL8043457 0.81 SOAT1 (0.47) SOAT2ACAT1SOAT1LMNAMAPT
SCHEMBL8041447 0.81 SOAT2 (0.47) SOAT2ACAT1SOAT1LMNAMAPT
SCHEMBL8049433 0.80 SOAT2 (0.46) SOAT2ACAT1SOAT1LMNAMAPT
SCHEMBL8042243 0.80 SOAT2 (0.46) SOAT2ACAT1SOAT1LMNAMAPT
SCHEMBL8049340 0.79 SOAT1 (0.45) SOAT2ACAT1SOAT1LMNAMAPT
SCHEMBL13249165 0.75 SOAT2 (0.73) SOAT2ACAT1SOAT1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135785-A1 Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof PIERRE FABRE MEDICAMENT (FR) 2006-06-22 — — US disclosed
EP-1558590-A1 ALPHA-PHENYL ACETANILIDE DERIVATIVES HAVING AN ACAT INHIBITING ACTIVITY AND THE THERAPEUTIC APPLICATION THEREOF PIERRE FABRE MEDICAMENT (FR) 2005-08-03 — — EP disclosed
WO-2004035552-A1 ALPHA-PHENYL ACETANILIDE DERIVATIVES HAVING AN ACAT INHIBITING ACTIVITY AND THE THERAPEUTIC APPLICATION THEREOF PIERRE FABRE MEDICAMENT (FR) 2004-04-29 — — WO disclosed
US-5990173-A ANTICHOLESTEROL AGENTS; TREATING ATHEROSCLEROSIS; ENZYME INHIBITORS OF ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE (ACAT) PIERRE FABRE MEDICAMENT (FR) 1999-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135785-A1 Alpha-phenyl acetanilide derivatives having an acat inhibiting activity and the therapeutic application thereof ACAT2, ACAT1, LCAT SOAT2 109/4885ACAT1 2/4885SOAT1 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.